117 related articles for article (PubMed ID: 36268941)
21. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Vinayak S; Tolaney SM; Schwartzberg L; Mita M; McCann G; Tan AR; Wahner-Hendrickson AE; Forero A; Anders C; Wulf GM; Dillon P; Lynce F; Zarwan C; Erban JK; Zhou Y; Buerstatte N; Graham JR; Arora S; Dezube BJ; Telli ML
JAMA Oncol; 2019 Aug; 5(8):1132-1140. PubMed ID: 31194225
[TBL] [Abstract][Full Text] [Related]
22. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
Lehmann BD; Abramson VG; Dees EC; Shah PD; Ballinger TJ; Isaacs C; Santa-Maria CA; An H; Gonzalez-Ericsson PI; Sanders ME; Newsom KC; Abramson RG; Sheng Q; Hsu CY; Shyr Y; Wolff AC; Pietenpol JA
JAMA Oncol; 2024 Feb; 10(2):193-201. PubMed ID: 38095878
[TBL] [Abstract][Full Text] [Related]
23. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy
Slamon DJ; Fasching PA; Hurvitz S; Chia S; Crown J; Martín M; Barrios CH; Bardia A; Im SA; Yardley DA; Untch M; Huang CS; Stroyakovskiy D; Xu B; Moroose RL; Loi S; Visco F; Bee-Munteanu V; Afenjar K; Fresco R; Taran T; Chakravartty A; Zarate JP; Lteif A; Hortobagyi GN
Ther Adv Med Oncol; 2023; 15():17588359231178125. PubMed ID: 37275963
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
O'Shaughnessy J; McIntyre K; Wilks S; Ma L; Block M; Andorsky D; Danso M; Locke T; Scales A; Wang Y
JAMA Netw Open; 2021 Apr; 4(4):e214103. PubMed ID: 33877311
[TBL] [Abstract][Full Text] [Related]
25. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
Earl H; Hiller L; Vallier AL; Loi S; McAdam K; Hughes-Davies L; Rea D; Howe D; Raynes K; Higgins HB; Wilcox M; Plummer C; Mahler-Araujo B; Provenzano E; Chhabra A; Gasson S; Balmer C; Abraham JE; Caldas C; Hall P; Shinkins B; McCabe C; Hulme C; Miles D; Wardley AM; Cameron DA; Dunn JA
Health Technol Assess; 2020 Aug; 24(40):1-190. PubMed ID: 32880572
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant medial versus entire supraclavicular lymph node irradiation in high-risk early breast cancer (SUCLANODE): a protocol for a multicenter, randomized, open-label, phase 3 trial.
Zhang L; Mei X; Hu Z; Yu B; Zhang C; Li Y; Liu K; Ma X; Ma J; Chen X; Meng J; Shi W; Wang X; Mo M; Shao Z; Zhang Z; Yu X; Guo X; Yang Z
BMC Cancer; 2024 Jan; 24(1):49. PubMed ID: 38195438
[TBL] [Abstract][Full Text] [Related]
27. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
Blackley EF; Loi S
Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
[TBL] [Abstract][Full Text] [Related]
28. Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial.
Wu S; Zhang L; Li H; Xu J; Jiang C; Sun T
Trials; 2020 May; 21(1):420. PubMed ID: 32448335
[TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
[TBL] [Abstract][Full Text] [Related]
30. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
[TBL] [Abstract][Full Text] [Related]
31. Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
Diéras V; Bonnefoi H; Alba E; Awada A; Coudert B; Pivot X; Gligorov J; Jager A; Zambelli S; Lindeman GJ; Charpentier E; Emmons GT; Garcia-Ribas I; Paridaens R; Verweij J
Breast Cancer Res Treat; 2019 Sep; 177(2):383-393. PubMed ID: 31172407
[TBL] [Abstract][Full Text] [Related]
32. Research advances and new challenges in overcoming triple-negative breast cancer.
Zong Y; Pegram M
Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial.
de Pádua Souza C; Carneiro ASB; de Oliveira Lessa AC; Lacerda DC; Paiva CE; Zorzetto MMC; de Freitas AJA; Santana IVV; de Oliveira MA; Palmero EI; Marques MMC; Reinert T
Breast Cancer Res Treat; 2023 Nov; 202(1):57-65. PubMed ID: 37578666
[TBL] [Abstract][Full Text] [Related]
34. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.
Friedl TWP; Fehm T; Müller V; Lichtenegger W; Blohmer J; Lorenz R; Forstbauer H; Fink V; Bekes I; Huober J; Jückstock J; Schneeweiss A; Tesch H; Mahner S; Brucker SY; Heinrich G; Häberle L; Fasching PA; Beckmann MW; Coleman RE; Janni W; Rack B
JAMA Oncol; 2021 Aug; 7(8):1149-1157. PubMed ID: 34165508
[TBL] [Abstract][Full Text] [Related]
35. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
[TBL] [Abstract][Full Text] [Related]
36. Development of Globo-H cancer vaccine.
Danishefsky SJ; Shue YK; Chang MN; Wong CH
Acc Chem Res; 2015 Mar; 48(3):643-52. PubMed ID: 25665650
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim SB; Sohn J; Im SA; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
Ann Oncol; 2020 May; 31(5):569-581. PubMed ID: 32278621
[TBL] [Abstract][Full Text] [Related]
38. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
